A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

What Was Tested

This registered phase 3 trial tested Retatrutide for sleep apnea (obstructive).

The study will last about 89 weeks and will include up to 24 visits.

It had four arms (groups): one (experimental), one (experimental), one (experimental) and Placebo (placebo comparator).

Participants will receive retatrutide subcutaneously (SC).

Participants will receive retatrutide SC.

Participants will receive retatrutide SC.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 1152 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a body mass index (BMI) greater than or equal to 27.0 kilogram/square meter (kg/m ²). Have Type 2 Diabetes (T2D). Are on stable treatment for T2D for at least 90 days. Have a history of at least one unsuccessful dietary effort to lose body weight. Previously diagnosed with OSA.

The full record lists 8 inclusion and 9 exclusion criteria; among the exclusions: have a self-reported or documented change in body weight \>5 kg (11 pounds) within 90 days; have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening; have a prior or planned surgical treatment for obesity.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

The sleep apnea (obstructive) participants were allocated by chance, so the Retatrutide group and the comparison group should start out alike.

The Retatrutide group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the sleep apnea (obstructive) participants and researchers unaware of who received Retatrutide.

Those kept unaware of assignments: participant and investigator.

It started in 2023-07-11 with completion listed for 2026-06-16.

It ran at 98 sites in United States (40), India (14), Australia (12), Mexico (12), Spain (7) and Romania (6).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percent Change from Baseline in Body Weight (time frame: Baseline, Week 80). Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset (time frame: Baseline, Week 80).

It also tracked 14 secondary outcomes, for example Change from Baseline in Body Mass Index (BMI), Change from Baseline in Waist Circumference, Change from Baseline in Systolic Blood Pressure (SBP), Change from Baseline in Diastolic Blood Pressure (DBP), Percent Change from Baseline in Total Cholesterol and Percent Change from Baseline in Triglycerides.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Retatrutide in 1152 people with sleep apnea (obstructive).

With 1152 participants it is a large trial for this field.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Retatrutide compound page, Sleep apnea (obstructive) research.